Your browser doesn't support javascript.
loading
First report of multi-drug resistant tuberculosis in a systemic lupus erythematosus patient.
Dorjee, Kunchok; Dierberg, Kerry L; Sadutshang, Tsetan D; Reingold, Arthur L.
Afiliação
  • Dorjee K; Division of Epidemiology, School of Public Health, University of California, Berkeley, 113 Haviland Hall #7358, Berkeley, CA, 94720-7358, USA. kunchok@berkeley.edu.
  • Dierberg KL; The Tibetan Delek Hospital, Dharamshala, Himachal Pradesh, India. kunchok@berkeley.edu.
  • Sadutshang TD; Johns Hopkins University School of Medicine, Baltimore, MD, USA. kdierbe1@jhmi.edu.
  • Reingold AL; The Tibetan Delek Hospital, Dharamshala, Himachal Pradesh, India. sadutshang@yahoo.com.
BMC Res Notes ; 8: 337, 2015 Aug 06.
Article em En | MEDLINE | ID: mdl-26245637
ABSTRACT

BACKGROUND:

Treatment of a multi-drug resistant tuberculosis (MDR-TB) patient is clinically challenging, requiring a minimum of 18 months of therapy. Its occurrence in a systemic lupus erythromatosus (SLE) patient may complicate management of both MDR-TB and SLE. This is the first descriptive report of MDR-TB in an SLE patient. CASE PRESENTATION A 19-year old female receiving long-term prednisolone for SLE was diagnosed with MDR-TB. She was started on MDR-TB treatment regimen and prednisolone was replaced with azathioprine. After an initial response to therapy, patient experienced a flare of lupus symptoms. Imaging studies revealed avascular necrosis of right femoral head. She was then treated with intravenous methyl-prednisolone, followed by maintenance corticosteroid. Azathioprine was discontinued due to hematological toxicity and failure to control SLE. Her symptoms of lupus regressed and did not re-occur for the duration of her MDR-TB treatment. Patient was declared cured of MDR-TB after 18 months of ATT. She is currently scheduled for a total hip replacement surgery.

CONCLUSIONS:

This case highlights the challenges of simultaneously managing MDR-TB and SLE in a patient due to their over-lapping signs and symptoms, drug-drug interactions, and the need for use of immunomodulatory agents in the absence of standard guidelines and documented previous experiences. Our experience underscores the importance of appropriate selection of treatment regimens for both MDR-TB and SLE.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose Resistente a Múltiplos Medicamentos / Lúpus Eritematoso Sistêmico Tipo de estudo: Guideline Limite: Adult / Female / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose Resistente a Múltiplos Medicamentos / Lúpus Eritematoso Sistêmico Tipo de estudo: Guideline Limite: Adult / Female / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article